ADMA Biologics (ADMA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of ADMA Biologics (ADMA)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Key Insights
Critical company metrics and information
Share Price
$19.82Market Cap
$4.69 BillionTotal Outstanding Shares
236.39 Million SharesTotal Employees
624Dividend
No dividendIPO Date
October 17, 2013SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.admabiologics.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $86.05 Million |
| Net Cash Flow, Continuing | $12.55 Million |
| Net Cash Flow From Financing Activities | $-66.27 Million |
| Net Cash Flow | $12.55 Million |
| Net Cash Flow From Investing Activities, Continuing | $-7.23 Million |
| Net Cash Flow From Financing Activities, Continuing | $-66.27 Million |
| Net Cash Flow From Investing Activities | $-7.23 Million |
| Net Cash Flow From Operating Activities | $86.05 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Operating Income/Loss | $114.89 Million |
| Diluted Earnings Per Share | $0.27 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Benefits Costs and Expenses | $23.00 Million |
| Costs And Expenses | $259.58 Million |
| Selling, General, and Administrative Expenses | $66.34 Million |
| Depreciation and Amortization | $8.21 Million |
| Basic Average Shares | $232.63 Million |
| Operating Expenses | $72.41 Million |
| Nonoperating Income/Loss | $-41.54 Million |
| Net Income/Loss Attributable To Parent | $68.13 Million |
| Basic Earnings Per Share | $0.29 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Research and Development | $1.87 Million |
| Income/Loss From Continuing Operations After Tax | $68.13 Million |
| Income/Loss From Continuing Operations Before Tax | $359.81 Million |
| Revenues | $382.81 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Cost Of Revenue | $195.50 Million |
| Gross Profit | $187.31 Million |
| Net Income/Loss | $68.13 Million |
| Income Tax Expense/Benefit | $5.22 Million |
| Diluted Average Shares | $242.44 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $68.13 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $72.42 Million |
| Accounts Payable | $16.02 Million |
| Equity | $231.89 Million |
| Other Non-current Assets | $18.25 Million |
| Current Liabilities | $44.89 Million |
| Noncurrent Liabilities | $113.84 Million |
| Other Current Liabilities | $28.87 Million |
| Equity Attributable To Parent | $231.89 Million |
| Other Current Assets | $146.39 Million |
| Inventory | $171.80 Million |
| Assets | $390.62 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Current Assets | $318.19 Million |
| Intangible Assets | $485000.00 |
| Liabilities | $158.73 Million |
| Liabilities And Equity | $390.62 Million |
| Fixed Assets | $53.69 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.